Talent mapping for life sciences: mapping scarce talent in tight clusters

In life sciences, the constraint is rarely demand — it's supply. The people who can run a clinical programme in a given therapeutic area, own a regulatory submission, or lead a modality like cell and gene therapy are few, deeply specialised, and concentrated in a handful of places. A life-sciences talent map is a read on that scarce, clustered market: who the named experts are, where they sit, and whether they'd ever move. You don't map life-sciences talent broadly. You map a discipline, in a place.

That scarcity is what makes mapping sell here. When the credible pool for a role is small and known, a client can't post their way to it — they have to know who exists first, and that's intelligence they'll pay for.

How scarce is the talent, and where is it?

Scarce in the way that matters, and tightly concentrated.

The headline number is large, but it fractures fast. Half of it sits in the Golden Triangle of Oxford, Cambridge and London, and within any one discipline — say, regulatory affairs for advanced therapies — the people who have done the job are a recognisable, finite group. A map is how you find that group and read whether geography, equity or a stalled pipeline makes any of them reachable.

What a life-sciences talent map contains

A useful map is specific along three axes at once — discipline, therapeutic area, and place:

• The function — discovery and R&D, clinical development, regulatory affairs, medical affairs, CMC and manufacturing, quality, and the commercial side. Each is a separate pool with separate scarcity.
• Therapeutic area and modality — oncology, rare disease, immunology, cell and gene, mRNA. Talent doesn't transfer cleanly across them, so the map has to be drawn to the client's exact space.
• The named senior people — the principal investigators, clinical leads and regulatory heads, read through what they've published, the trials they've run, and the submissions they've landed.
• Geography and mobility — which cluster they're in, and whether they'd relocate, which in this sector is often the deciding factor.
• Compensation and structure — the trade a candidate is weighing between equity in a venture-backed biotech and stability in big pharma, and the particular pull and friction of an academia-to-industry move.

The employer set spans big pharma, mid-cap and early-stage biotech, CROs and CDMOs, medtech, and — uniquely to this sector — academia and research institutes, which are both the source of much of the talent and a competitor for it. Reconstructing how a rival's R&D or clinical function is built is competitor talent mapping; for the deliverable itself, see what goes in a market map.

Why life-sciences clients commission a map

The briefs follow the science and the money:

• A biotech that just raised. A Series B closes and a clinical and regulatory function has to be built at speed — out of a pool that's tiny to begin with.
• A pharma entering a new therapeutic area or modality. The internal expertise doesn't exist yet, so they need to see who in the market does.
• A site or cluster decision. Where to put a UK function, given where the talent actually is — a market-entry talent map with a scientific overlay.
• Replacing a departing scientific leader. A head of R&D or a clinical lead leaves, and the question is who, externally, could step in — quietly. That's succession talent mapping.

Each is an R&D or board-level decision, funded as intelligence rather than as a placement fee.

How to build one

The underlying method is the same as any sector map — boundary, company universe, people, intelligence, presentation — and it's set out in how to market map a sector. Don't reinvent it; specialise it.

The life-sciences-specific moves: draw the boundary along all three axes at once (discipline plus therapeutic area plus geography), because a looser brief produces a useless map. Use the sector's own signals the way you'd use funding rounds elsewhere — publications, trial registries, and conference faculty all tell you who the real experts are. And hold in mind that academic and industry seniority don't map one-to-one, so a glittering publication record isn't the same as someone who can run an industry function.

Pricing it, and turning it into a search

Price it as the strategic, R&D-funded work it is — a fixed fee scaled to how many disciplines and therapeutic areas the map has to cover, not a day rate. The packaging and pricing sit in how to sell talent mapping as a service.

And line up the follow-through. In a market this scarce, the agency that mapped the field is the one that gets asked to land the hire when the client is ready to move. The map is what you bill today; the search for a needle in a very small haystack is what it sets up.

Frequently asked questions

What makes life sciences talent mapping different from a normal sector map?

The talent is scarce and hyper-specialised, and it isn't fungible. Someone who can run an oncology clinical programme is not interchangeable with a rare-disease lead, and a cell-and-gene scientist is not a small-molecule one. On top of that, the talent clusters geographically. So a life-sciences map is never 'scientists' — it's a specific discipline, in a specific therapeutic area or modality, in a specific place.

Who buys a life sciences talent map?

A biotech that has just raised and needs to build a clinical or regulatory function fast, a pharma standing up a new therapeutic area, a CRO scaling delivery, or a company choosing where to put a UK site. The budget sits with R&D or strategy, because the map informs a build decision, not a single vacancy.

Is the talent really that scarce?

At the headline level the sector employs around 359,600 people. But within a single therapeutic area or modality the credible senior pool is small, and the Office for Life Sciences projects demand for tens of thousands of new and replacement roles over the next decade. Scarcity here is structural, which is exactly the condition under which mapping beats advertising.